The account includes products such as Coppertone, Afrin, Lotrimin, Tinactin and Dr. Scholl's.
The decision came after a review that included Havas Advertising's Media Planning Group, New York, and independent Horizon Media, New York.
Zenith also handles Schering's $170 million-plus direct-to-consumer pharmaceutical account, which includes Claritin. The incumbent was TN Media, New York. -- David Goetzl
Copyright July 2001, Crain Communications Inc.